Results 101 to 110 of about 17,702 (177)

Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis

Therapeutic Advances in Infectious Disease
Background: Echinocandins are recommended as an initial treatment for invasive candidiasis. Although safety and efficacy profiles of both anidulafungin and caspofungin are well established, direct head-to-head comparisons have not been reported before ...
Reem Hasan Elajez, Dana Bakdach, Sara Al Balushi, Ahmed Zaqout, Rand Alattar, Tasneem Abdallah, Waleed Awouda, Godwin Wilson, Walid Al-Wali, Emad Ibrahim, Hussam Alsoub   +10 more
doaj   +1 more source

Effi cacy and safety of caspofungin in obese patients

, 2011
patient weight is a factor in determining dosing for some other antifungal agents (e.g., poylene formulations [1]). Hence, questions have arisen regarding use of weight as a factor in determining caspofungin dosing for obese adults.
Desmond M. Ryan, Nicholas A. Kartsonis, Robert J. Lupinacci   +2 more
core   +1 more source

Evolutionary dynamics in gut-colonizing Candida glabrata during caspofungin therapy: Emergence of clinically important mutations in sphingolipid biosynthesis.

PLoS Pathogens
Invasive fungal infections are associated with high mortality, which is exacerbated by the limited antifungal drug armamentarium and increasing antifungal drug resistance.
Yasmine Hassoun, Ariel A Aptekmann, Mikhail V Keniya, Rosa Y Gomez, Nicole Alayo, Giovanna Novi, Christopher Quinteros, Firat Kaya, Matthew Zimmerman, Diego H Caceres, Nancy A Chow, David S Perlin, Erika Shor   +12 more
doaj   +1 more source

Enhanced efficacy of synergistic combinations of antimicrobial peptides with caspofungin versus Candida albicans in insect and murine models of systemic infection

, 2013
The objective of this study was to determine whether combinations of antimicrobial peptides (AMPs) with caspofungin display enhanced antifungal activity versus Candida albicans in vitro and in vivo.
Coote, Peter John, MacCallum, Donna, Desbois, Andrew P, MacCallum, Donna M, Desbois, Andrew, Coote, Peter J   +5 more
core   +1 more source

The efficacy of luliconazole and caspofungin on planktonic and biofilm of Candida albicans from different sources

Iranian Journal of Microbiology
Background and Objectives: The ability of Candida albicans to produce biofilm is considered an important pathogenic factor. In addition, the low sensitivity of biofilms to antifungal drugs is a challenge for patients, clinicians, and laboratory workers.
Mahboubeh Shabanzadeh, Ali Rezaei-Matehkolaei, Ali Zarei Mahmoudabadi   +2 more
doaj   +1 more source

Compensatory response of the cell wall integrity pathway and chitin to caspofungin exposure in Candida glabrata

, 2007
Background: Studies in Saccharomyces cerevisiae and Candida albicans have reported an up-regulation of the cell wall integrity pathway and an increase in cell wall chitin following caspofungin exposure.
Cota, Jason M.
core   +1 more source

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

, 2004
Background. Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immuno-compromised patients. Echinocandins are novel antifungal molecules with in vitro and in vivo activity against Aspergillus species. Methods.
Walsh, TJ, D, Petrikkos, G, Raad, I, Selleslag, Sable, CA, Maertens, J, Denning, DW, Boogaerts, M, Patterson, TF, Petersen, FB, Ngai, A, Kartsonis, NA, Taylor, A, Caspofungin Salvage Aspergillosis   +14 more
core   +1 more source

Ocular penetration of caspofungin in a rabbit uveitis model [PDF]

, 2018
Background: Little is known about the ocular penetration of echinocandin antifungals. We studied the ocular distribution of systemically administered caspofungin in a rabbit uveitis model.
Zimmerli, Stefan, Goldblum, David, Thormann, Wolfgang, Theurillat, Regula, Frueh, Beatrice, Fausch, Kathrin   +5 more
core  

Walsh & Hoyt: Caspofungin

, 2005
Caspofungin is the first approved agent from a class of antifungal agents called the echinocandins. Its mechanism of action is unique in that it attacks the cell wall of the fungus, as opposed to its cell membrane.
Joel M. Weinstein, MD
core  

Context-dependent immunomodulation by caspofungin: inflammatory attenuation involving spleen tyrosine kinase signaling in monocytic-cell systems versus pathogen-mediated immune amplification. [PDF]

Microlife
Itoh K, Iwasaki H, Ikawa M, Mitsuke Y.
europepmc   +1 more source